U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Commission File Number 000-51833

Verbena Pharmaceuticals Inc.

(Exact name of registrant as specified in its charter)


Delaware		20-4142447
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

843 Persimmon Lane
Langhorne PA		19047
(Address of principal executive offices)		(zip code)

Registrant’s telephone number, including area code:

((215-741-7006)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Item 84.0102 ~~Other~~Non-Reliance ~~Events~~on ~~Forward~~Previously ~~Split~~Issued Financial Statements or a Related Audit Report or Completed Interim Review The authorized officer of ~~Common~~the ~~Stock~~company, OnRobert ~~June~~Schneiderman 4, concluded, on August 6, 2009, that the ~~Company~~company’s ~~completed~~previously aissued ~~forward~~financial ~~stock~~statements ~~split~~for the quarterly periods ending March 31, 2008, and June 30, 2008 no longer should be relied upon because of ~~its~~the ~~common~~omission ~~stock~~of oncertain ainformation ~~ratio~~as described below. Those financial statements did not include the impact of ~~seven~~the ~~shares~~$1,300.00 note payable to Steven Urbanski as payment for ~~every~~accounting ~~one~~services ~~share~~performed offor the Company. The ~~record~~subsequent ~~date~~statements offor the ~~forward~~period ~~stock~~ending ~~split~~9-30-2008 ~~was~~and ~~June~~12-31-2008 5,included ~~2009,~~the information on the ~~payment~~aforementioned ~~date~~note payable. The authorized officer of the ~~forward~~company ~~split~~discussed ~~was~~this ~~June~~omission 8,with ~~2009,~~the independent accountant employed by the company. The Company intends to file an amended 10-Q for the period ended 3-31-09 and the10-Q for the experiod ended 6-~~dividend~~30-09 ~~date~~on or before 8-14-2009 which will contain restated statements of operations and cash flows for the ~~forward~~period ~~split~~ended ~~was~~March 31, 2008 and June 930, ~~2009~~2008.

Item 9.01 Financial Statements and Exhibits

(a) Financial statements of businesses acquired.

Not applicable.

(b) Pro forma financial information.

Not applicable.

(d) Exhibits

Not applicable.

SIGNATURES

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	VERBENA PHARMACEUTICALS INC.
Dated: June 4, 2008	By:	/s/ Robert Schneiderman
Dated: August 7, 2009	By:	/s/ Robert Schneiderman
		Name: Robert Schneiderman Title: President, Secretary and Director

Filing Compare · VERBENA PHARMACEUTICALS INC